British Journal of Ophthalmology · 2020 · 49 citations · 24 references
MedicineOphthalmologyPharmacologyClinical OptometryOcular DiseaseOcular PharmacologyMacular DegenerationMacular DiseaseMacular DisordersRetinal DisordersRetinal PharmacotherapyRetinal Pigment EpitheliumPrimary Outcome AnalysisRetinal Pigment Epithelium TargetingSubjectsSuppression
BACKGROUND/AIMS: Stargardt disease is a rare, inherited, degenerative disease of the retina that is the most common type of hereditary macular dystrophy. Currently, no approved treatments for the disease exist. The purpose of this study was to characterise the pharmacodynamics of emixustat, an orally available small molecule that targets the retinal pigment epithelium-specific 65 kDa protein (RPE65), in subjects with macular atrophy secondary to Stargardt disease. METHODS: In this multicentre study conducted at six study sites in the USA, 23 subjects with macular atrophy secondary to Stargardt disease were randomised to one of three doses of daily emixustat (2.5 mg, 5 mg or 10 mg) and treated for 1 month. The primary outcome was the suppression of the rod b-wave recovery rate on electroretinography after photobleaching, which is an indirect measure of RPE65 inhibition. RESULTS: Subjects who received 10 mg emixustat showed near-complete suppression of the rod b-wave amplitude recovery rate postphotobleaching (mean=91.86%, median=96.69%), whereas those who received 5 mg showed moderate suppression (mean=52.2%, median=68.0%). No effect was observed for subjects who received 2.5 mg emixustat (mean=-3.31%, median=-12.23%). The adverse event profile was consistent with prior studies in other patient populations and consisted primarily of ocular adverse events likely related to RPE65 inhibition. CONCLUSION: This study demonstrated dose-dependent suppression of rod b-wave amplitude recovery postphotobleaching, confirming emixustat's biological activity in patients with Stargardt disease. These findings informed dose selection for a 24-month phase 3 trial (SeaSTAR Study) that is now comparing emixustat to placebo in the treatment of Stargardt disease-associated macular atrophy.
24
Isomerization and Oxidation of Vitamin A in Cone-Dominant Retinas
Nathan L. Mata, Roxana A. Radu, R Clemmons et al. · Neuron · 2002 · 379 citations · Full text
ABCA4 disease progression and a proposed strategy for gene therapy
Artur V. Cideciyan, Małgorzata Świder, Tomás S. Alemán et al. · Human Molecular Genetics · 2008 · 186 citations · Full text
Medicine, Genetics, Ophthalmology +15